Neu Differentiation Factor Upregulates Epidermal Migration and Integrin Expression in Excisional Wounds

Dimitry M. Danilenko,* Brian D. Ring,* John Z. Lu,* John E. Tarpley,* David Chang,† Naill Liu,§ Duanzhi Wen,|| and Glenn F. Pierce*†

Departments of *Experimental Pathology, †Immunology, ‡Research Process Development, and ||Mammalian Cell Molecular Biology, Amgen, Inc., Thousand Oaks, California 91320-1789

Abstract

Neu differentiation factor (NDF) is a 44-kD glycoprotein which was isolated from ras-transformed rat fibroblasts and indirectly induces tyrosine phosphorylation of the HER-2/neu receptor via binding to either the HER-3 or HER-4 receptor. NDF contains a receptor binding epidermal growth factor (EGF)-like domain and is a member of the EGF family. There are multiple different isoforms of NDF which arise by alternative splicing of a single gene. To date, in vivo biologic activities have not been demonstrated for any NDF isoform. Since NDF, HER-2/neu, and HER-3 are present in skin, and other EGF family members can influence wound keratinocytes in vivo, we investigated whether NDF would stimulate epidermal migration and proliferation in a rabbit ear model of excisional wound repair. In this model, recombinant human NDF-α2 (rhNDF-α2), applied once at the time of wounding, induced a highly significant increase in both epidermal migration and epidermal thickness at doses ranging from 4 to 40 μg/cm². In contrast, rhNDF-α1, rhNDF-β1, and rhNDF-β2 had no apparent biologic effects in this model. rhNDF-α2 also induced increased neoepidermal expression of α2 and α4 integrins, two of the earliest integrins to appear during epidermal migration. In addition, rhNDF-α2-treated wounds exhibited increased neoepidermal expression of cytokeratin 10 and filaggrin, both epidermal differentiation markers. NDF α isoforms were expressed in dermal fibroblasts of wounded and unwounded skin, while both HER-2/neu and HER-3 were expressed in unwounded epidermis and dermal adnexa. In wounds, HER-2/neu expression was markedly decreased in the wound neoepidermis while neoepidermal HER-3 expression was markedly upregulated. Taken together, these results suggest that endogenous NDF-α2 may function as a paracrine mediator directing initial epidermal migration during cutaneous tissue repair. (J. Clin. Invest. 1995. 95:842–851.) Key words: adhesion molecules • growth factors • immunohistochemistry • keratinocytes • wound healing

Introduction

Neu differentiation factor (NDF)¹ is a 44-kD glycoprotein which was isolated from ras-transformed rat fibroblasts and was shown to induce tyrosine phosphorylation of the HER-2/neu receptor on several human mammary adenocarcinoma cell lines (1, 2). A human homologue of NDF, termed heregulin, was independently isolated from conditioned medium of MDA-MB-231 human mammary carcinoma cells and was shown to induce tyrosine phosphorylation of the HER-2/neu receptor in MCF-7 human mammary carcinoma cells (3). When NDF/heregulin was originally identified, it was believed to be the specific ligand for the HER-2/neu receptor. More recent studies have shown, however, that two recently isolated members of the epidermal growth factor receptor (EGFR) family, HER-3 and HER-4 (4–6), are the actual specific receptors for NDF/heregulin (7–9) and that HER-2/neu is tyrosine phosphorylated through activation of either the HER-3 or HER-4 receptor by NDF/heregulin (7–9).

NDF is a member of the EGF family of growth factors, a family which includes transforming growth factor-α (TGF-α), amphiregulin, betacellulin, heparin-binding EGF-like growth factor, and vaccinia virus growth factor (10–14). Within the EGF growth factor family, only NDF has been shown to activate HER-2/neu (1, 2). In addition, NDF does not bind to EGFR (1, 3), while all other known EGF family members bind EGFR (13, 15). There are at least six distinct NDF precursor proteins (proNDFs), which are identical in their first 213 amino acid residues. This 213–amino acid stretch includes a basic NH₂ terminus which is proteolytically cleaved at amino acid 14 in naturally occurring rat NDF, an immunoglobulin-like domain, a spacer domain, and two disulfide loops of a receptor binding EGF-like domain (16). These proNDFs give rise to at least 12 different isoforms of NDF which arise by alternative splicing of a single NDF gene (16). Isoform structural variation arises in three domains which COOH-terminally flank the identical 213 amino acid residues (16). The first variable domain is a COOH-terminal portion of the receptor binding EGF-like domain and distinguishes α and β isoforms. An adjacent juxtamembrane region of the EGF-like domain is the second variable


Received for publication 15 April 1994 and in revised form 4 October 1994.

© The American Society for Clinical Investigation, Inc.
0021-9738/95/02/0842/10 $2.00
Volume 95, February 1995, 842–851

1. Abbreviations used in this paper: bFGF, basic fibroblast growth factor; BrdU, bromodeoxyuridine; CK, cytokeratin; EGFR, EGF receptor; H&E, hematoxylin and eosin; NDF, neu differentiation factor; proNDF, NDF precursor proteins; rh, recombinant human.
domain and gives rise to isoforms 1–4. Lastly, variability in the length of the cytoplasmic tail determines isoforms a, b, and c (16) (Fig. 1).

Some NDF isoforms display partial tissue specificity. ProNDF-α2 is the predominant isoform in mesenchymal cells, including fibroblasts, while proNDF-β1 is the major isoform in nervous tissue (16). Several other NDF isoforms were originally cloned from nervous tissue and later were found to represent splice variants of NDF. These molecules include a group of Schwann cell mitogens collectively termed glial growth factors (17) and a factor, termed acetylcholine receptor inducing activity (ARIA), which stimulates acetylcholine receptor synthesis at the neuromuscular junction (18).

Although the HER-2/neu receptor is not the specific receptor for NDF, NDF’s biologic effects are mediated through tyrosine phosphorylation of HER-2/neu via HER-3 and HER-4 tyrosine phosphorylation in cells which coexpress both receptors (7, 9). Both HER-2/ neu and HER-3 are distributed over a relatively wide range of epithelial tissues, including the skin (19–21), while precise tissue localization of HER-4 has not yet been done. Immunohistochemical studies have localized both HER-2/ neu and HER-3 to the basal and suprabasal layers of the epidermis (19, 21, 22), as well as to epidermal adnexa (20, 21). NDF has been shown to be expressed in the skin of embryonic mice by in situ hybridization, although the specific cell type could not be discerned (23). The coexpression of NDF and both the HER-2/neu and HER-3 receptors in the skin, coupled with the ability of NDF to arrest proliferation and induce differentiation in a human breast carcinoma cell line overexpressing HER-2/neu (1), suggests that the interaction of NDF with the HER-2/neu–HER-3 receptor complex may play an important role in the regulation of normal epidermal growth and differentiation.

To date, in vivo biologic activities have not yet been demonstrated for NDF, but EGF, TGF-α, and vaccinia virus growth factor have all been shown to variably stimulate in vivo wound reepithelialization (24–27). Since NDF is structurally related to these three growth factors, but stimulates a distinct receptor, we sought to investigate whether NDF would influence epidermal migration in an in vivo model of excisional deep partial thickness wound repair. We chose to first use the NDF-α2 isoform, since this isoform is the predominant isoform in mesenchymal cells and had been localized to the skin (16, 23), and then to compare the effects obtained using the NDF-α2 isoform with the effects observed with other NDF isoforms.

**Methods**

Recombinant NDF. Recombinant human NDF-α2 14-241 (rhNDF-α2), rhNDF-α1 14-249, rhNDF-β1 14-246, and rhNDF-β2 14-238 were each produced in *Escherichia coli*, refolded, and purified to homogeneity by conventional techniques, and tested endotoxin free. Each isoform was determined to have bioactivity by its ability to induce tyrosine phosphorylation of p185 Neu in MDA-MB453 human breast carcinoma cells at concentrations as low as 1 ng/ml (22 pM) (1), which was equivalent to the bioactivity of Chinese hamster ovary cell–derived rat NDF-α2 (16).

Rabbit ear excisional wound model. Female, New Zealand White rabbits (3.5–4.0 kg) (Western Oregon Rabbit Co., Philomath, OR) were used for all experiments. The rabbit full thickness dermal wound model (27) was modified by removing cartilage in addition to the overlying epidermis and dermis (Fig. 2). In this model, the wound heals by sprouting of adnexa from the opposite side of the ear as well as by migration of epidermal keratinocytes from the wound margins (28). A 6-mm trephine was used to aseptically create four 0.25-cm² wounds on each ear. Immediately after wounding of both ears, 5 μl of rhNDF-α2 at specified concentrations in phosphate-buffered saline (PBS), or 5 μl of PBS alone (vehicle control), was placed within the wound bed, and the wounds were covered with Tegaderm occlusive dressing (3M Microbiology Products, St. Paul, MN). 30 h and 3, 4, or 5 d after wounding, the rabbits were killed, and all wounds were excised from the ears. Each wound was bisected with one half fixed in Omnifix II (Al-Con Genetics, Inc., Melville, NY) for routine histologic evaluation and the other half embedded in OCT media (Miles Inc., Elkhart, IN) and snap frozen in isopentane chilled to its freezing point in liquid nitrogen for integrin, NDF, and HER-2/neu immunohistochemical staining.

Assessment of reepithelialization and wound healing. 3-μm thick, hematoxylin and eosin (H&E)-stained sections of each wound were assessed for reepithelialization and epithelial thickness using several different measurements (Fig. 2). The epithelial gap (EG) is a linear measurement taken between the tongues of migrating new epithelium from each wound margin. The cartilage gap (CG) is the diameter of the wound measured between the cartilage plates at each margin. Both of these measurements were done with a calibrated ocular micrometer using the 4X objective on a Nikon Optiphot microscope. The new epithelium (NE) was derived by subtracting the EG from the CG, thus
standardizing any variability which might have been present in wound diameter. The epithelial area is a measurement of all the epithelium that has migrated into the wound bed from each cartilage margin inward and was measured via a calibrated Quantimet 520 image analyzer (Leica Inc., Deerfield, IL) coupled to a Nikon Optiphot microscope. For assessment of possible rhNDF effects on dermal cellular components, the granulation tissue area (GTA), a measurement of all wound bed tissue exclusive of epithelium, was also done on a Quantimet 520 image analyzer. All wound measurements were sorted by dose, and each dose was analyzed versus the vehicle control using one way analysis of variance (two-tailed) coupled with the Bonferroni/Dunn post-hoc test at a 5% significance level (Statview 4.0; Abacus Concepts, Inc., Berkeley, CA). Results are reported as mean±SE standard error.

Assessment of proliferation using anti-bromodeoxyuridine (BrdU). To assess BrdU incorporation, newly formed epithelial tissues (30 min before wound harvest, each rabbit was injected intravenously with 50 mg/kg body wt of BrdU (Aldrich Chemical Co., Milwaukee, WI). BrdU in wound sections was detected by avidin-biotin complex immunoperoxidase staining using an anti-BrdU monoclonal antibody (Dako Corp., Carpinteria, CA) (28). Assessment of keratinocyte BrdU labeling was done by a blinded observer with an ocular micrometer using the 20× objective. Labeled and unlabeled keratinocytes in both basal and suprabasal compartments were counted from the tip of each new epithelial tongue a distance of 1.5 mm toward the wound margin (3 mm total). Unpaired, two-tailed Student’s t-tests at a 5% significance level on Statview 4.0 were used to compare treated versus control wounds, and results are reported as mean percent labeled keratinocytes±SE the standard error.

Immunohistochemical analysis and monoclonal antibody characterization. Omni-fixed, paraffin-embedded, 3-μm-thick wound sections were used for analysis of filaggrin, cytokerin 10 and 14, and HER-3 expression. Expression of the three keratinocyte differentiation markers was detected by avidin-biotin complex immunoperoxidase staining (28) using mAbs directed against human filaggrin (Biomedical Technologies, Inc., Stoughton, MA), human cytokeratin 10 (clone DE-K10; Dako Corp.), and human cytokeratin 14 (clone LL002; BioGenex Labs, San Ramon, CA). HER-3 expression was detected by a specific anti-human HER-3 mAb (clone RTJ.1, mouse IgM; Santa Cruz Biomedical, Santa Cruz, CA) using avidin-biotin complex immunoperoxidase as described previously (28), but with substitution of a biotinylated goat anti-mouse IgM secondary (Jackson Immunoresearch Laboratories, Inc., West Grove, PA). Because of high background staining in wound beds, HER-3-stained sections were also avidin-biotin blocked (Vector Labs, Inc., Burlingame, CA). Expression of integrins, NDF, and HER-2/Neu was also detected by avidin-biotin complex immunoperoxidase as above, but staining was done on 5-μm-thick frozen sections of wounds. The α2 integrin was detected with a mouse anti-human α2 integrin mAb (clone P1E6; Gibco BRL, Grand Island, NY), α2 integrin was detected with a mouse anti-human α2 integrin mAb (clone P1D6; Dako Corp.), and α2 integrin was detected with a rat anti-human α2 integrin mAb (clone GoH3; Amac, Inc., Westbrook, ME). A mouse anti-human α3 integrin mAb (clone P1B5; Dako Corp.) was used to detect α3 integrin but did not specifically stain rabbit tissues.

NDF was detected by two different anti-NDF mAbs produced by the authors. Anti-NDF mAbs were characterized using a BIAcore instrument (Pharmacia Biosensor, Uppsala, Sweden), which detects real-time biospecific interactions based on changes in optical properties at the surface of a sensor chip (29, 30) (data not shown), as well as by ELISA (data not shown) and slot blot analysis (Fig. 3). One anti-NDF mAb, 1H7A (mouse IgG2b), recognized only α isoforms of NDF and exhibited no reactivity with NDF β isoforms. The other anti-NDF mAb, 1H8C (mouse IgG2b), recognized both α and β NDF isoforms. Neither

Figure 2. H&E-stained histologic section of the modified rabbit ear partial thickness excisional wound model. Original magnification ×4. Bold arrows indicate wound margins. Ca, cartilage plate; CG, cartilage gap; EG, epithelial gap; GTA, granulation tissue area.

Figure 3. Slot blot reactivity of anti-NDF mAbs 1H7A and 1H8C, illustrating that mAb 1H7A only reacts with α isoforms of NDF, mAb 1H8C reacts with both α and β isoforms of NDF, and neither mAb cross-reacts with EGF or TGF-α.
anti-NDF mAb exhibited any cross-reactivity with EGF or TGF-α (Fig. 3). HER-2/neu was detected by a specific anti–HER-2/neu mAb, clone HER 20 (mouse IgG2a), which was also produced and characterized using BLAcore and ELISA by the authors (data not shown).

Assessment of epidermal differentiation and integrin expression. Replicate paraffin-embedded and frozen sections of eight representative rhNDF-α2–treated wounds and eight control wounds were stained for filagrin and cytokeratins 10 and 14 to assess epidermal differentiation and stained for α1 and α2 integrins to assess the extent of epidermal expression of these integrins. Slides were read, blinded, by a pathologist experienced in interpretation of immunohistochemical staining results (D. M. Danilenko), and subjectively evaluated on the intensity and extent of epidermal staining for each antigen evaluated. Each of the eight rhNDF-α2–treated wounds was then directly compared with the eight control wounds, and the number of rhNDF-α2–treated wounds exhibiting either greater intensity or extent (depending on the antigen evaluated) than the control wound exhibiting the greatest staining for each particular antigen (e.g., 7/8) was reported.

Results

rhNDF-α2 increases reepithelialization and epidermal thickness. rhNDF-α2–treated wounds exhibited significantly increased reepithelialization (new epithelium) versus control wounds 5 d after wounding at doses ranging from 0.4 to 40 μg/cm2 (Fig. 4A). There was a dose-dependent increase in reepithelialization between 0 and 0.4 μg/cm2, with higher doses not appreciably increasing reepithelialization. rhNDF-α2–treated wounds also exhibited a significant increase in the thickness of new epithelium (epithelial area) 5 d after wounding at doses ranging from 4 to 40 μg/cm2, with a dose-dependent increase evident at doses of 0.04 to 4 μg/cm2 (Fig. 4B). rhNDF-α2 also significantly increased reepithelialization and new epithelial area 4 d after wounding at a dose of 4 μg/cm2, the only dose tested (data not shown). In contrast to the epidermal effects induced by rhNDF-α2, the other NDF isoforms tested, rhNDF-α1, rhNDF-β1, and rhNDF-β2, did not have any significant effects on reepithelialization or new epithelial area 5 d after wounding (data not shown). There was no difference in granulation tissue area in any of the rhNDF isoform–treated wounds versus control wounds, indicating that the rhNDF effect was epithelial specific (data not shown).

rhNDF-α2 does not significantly increase epidermal proliferation. The number of proliferating basal and suprabasal keratinocytes labeled with BrdU was counted at three different time points: 30 h, 3 d (72 h), and 5 d (120 h) after wounding. There were no statistically significant differences in proliferating basal and suprabasal keratinocytes in control wounds versus wounds treated with rhNDF-α2 at any of the three time points at all tested doses, although there was a trend toward increased proliferation in both basal and suprabasal keratinocytes in rhNDF-α2–treated wounds 30 h after wounding (Table 1).

rhNDF-α2–treated wounds exhibit increased neoepidermal expression of differentiation markers. Immunoperoxidase staining for filagrin and cytokeratins (CK) 10 and 14 revealed that seven of eight rhNDF-α2–treated wounds exhibited increased expression of filagrin and CK10, both markers of epidermal terminal differentiation (31, 32), in the neoeoepidermis migrating across the wound bed when compared with control wounds. This increased expression of filagrin and CK10 in rhNDF-α2–treated wounds was largely confined to the oldest neoeoepidermis at the wound margins, although in some rhNDF-α2–treated wounds (those nearly or fully reepithelialized) filagrin was expressed in nearly all of the neoeoepidermis (Fig. 5, C and F). CK14, a marker of basal keratinocytes (32), was expressed to the same extent in the regenerating epidermis of both rhNDF-α2–treated and control wounds (Fig. 5, G and H).

rhNDF-α2 upregulates epidermal integrin expression. Since rhNDF-α2 induced marked epidermal migration across the wound bed, and both EGF and TGF-α promote in vitro keratinocyte migration on collagen via increased keratinocyte expression of the collagen binding αβ integrin (33), we investigated whether the accelerated migration induced by rhNDF-α2 might be due to increased epidermal integrin expression. In un-
Table I. Proliferating Basal and Suprabasal Keratinocytes in rhNDF-α2--treated Rabbit Ear Wounds versus Control Wounds

<table>
<thead>
<tr>
<th></th>
<th>30 h</th>
<th>72 h</th>
<th>120 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal keratinocytes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>11.91±5.20</td>
<td>25.70±2.13</td>
<td>28.00±1.57</td>
</tr>
<tr>
<td>rhNDF-α2</td>
<td>22.01±5.48</td>
<td>20.93±3.00</td>
<td>32.47±1.73</td>
</tr>
<tr>
<td>Suprabasal keratinocytes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>1.51±0.66</td>
<td>4.39±1.27</td>
<td>9.09±0.98</td>
</tr>
<tr>
<td>rhNDF-α2</td>
<td>3.90±0.98</td>
<td>2.81±0.34</td>
<td>11.38±1.10</td>
</tr>
</tbody>
</table>

Rabbits were injected intravenously with BrdU 30 min before harvest, and sections of wounds were immunohistochemically stained for BrdU. BrdU-labeled and unlabeled keratinocytes were counted by a blinded observer in both basal and suprabasal compartments a distance of 1.5 mm from the tip of each neopidermal tongue toward the wound margin (3 mm total). Wounds treated with 4 μg rhNDF-α2 per cm² were compared with control wounds using unpaired, two-tailed Student’s t tests at a 5% significance level. Results are reported as the mean percent BrdU-labeled keratinocytes ± the standard error. There are no statistically significant differences between rhNDF-α2--treated versus control wounds at any time point, although there is a trend toward increased basal and suprabasal keratinocyte proliferation in 30-h rhNDF-α2--treated wounds.

wounded skin, expression of α6 integrin, the α subunit of α6β1 integrin, a receptor for laminin and possibly epiligrin (34, 35), was restricted to basal keratinocytes of the epidermis and adnexa. In the normal migrating epidermis covering the wound bed of 5-d-old control wounds, however, the distribution of α6 integrin increased to include most or all suprabasal keratinocytes. In seven of eight rhNDF-α2--treated wounds 5 d after wounding, the distribution of α6 integrin in the migrating new epidermis became even more widespread than it was in the new epidermis of control wounds (Fig. 6, A and B). α6 integrin, the α subunit of α6β1 integrin, a fibronectin receptor (36), was not expressed at all in normal, unwounded epidermis, but was very weakly expressed in basal keratinocytes of the migrating new epidermis in some 5-d-old control wounds. In six of eight rhNDF-α2--treated wounds 5 d after wounding, α6 integrin was expressed on both basal and suprabasal keratinocytes and was more strongly expressed in the migrating epidermis than it was in wound controls, but the intensity of expression was not as pronounced as that observed with α6 integrin (Fig. 6, C and D). α2 integrin, the α subunit of α2β1 integrin, a receptor for type I and type IV collagen as well as epiligrin (34, 37), was expressed predominantly on endothelial cells and was expressed only very weakly on the basal epidermis in both rhNDF-α2--treated and control wounds 5 d after wounding (not shown).

Expression of HER-2/neu, HER-3, and NDF epitopes in normal and wounded skin. HER-2/neu, as detected by mAb HER 20, and HER-3, as detected by mAb RTJ 1, were both expressed by epidermal and follicular keratinocytes, but exhibited markedly different levels of expression in wounded versus unwounded epidermis. HER-2/neu was expressed predominantly on keratinocytes in the basal cell layer and lower stratum spinosum of unwounded epidermis as well as in the basal epithelium of dermal adnexa (Fig. 7 A). In migrating wound neopidermis, HER-2/neu expression was markedly decreased as detected by decreased immunoperoxidase staining intensity in both rhNDF-α2--treated and control wounds (Fig. 7 B). HER-3 was weakly expressed by basal keratinocytes in normal epidermis, but was strongly expressed by follicular keratinocytes in the hair bulb and inner root sheath as well as by follicular keratin (Fig. 7 C). In contrast to HER-2/neu expression, which markedly decreased in the neopidermis, HER-3 expression was markedly increased in all keratinocytes of the migrating neopidermis in both control and rhNDF-α2--treated wounds (Fig. 7 D).

NDF as detected by both the α isoform–specific mAb, 1H7A, and by 1H8C, which detects both α and β NDF isoforms, was expressed by dermal fibroblasts within and adjacent to the wound bed (Fig. 7, E and F). There were no differences in NDF expression in rhNDF-α2--treated wounds versus control wounds.

Discussion

In this study, we have shown that rhNDF-α2, but not rhNDF-α1, rhNDF-β1, or rhNDF-β2, accelerates epidermal migration with normal epidermal differentiation but does not induce significant sustained keratinocyte proliferation in rabbit partial thickness excisional wounds. These epidermal effects contrast those described for two other members of the EGF family, EGF and TGF-α, both of which induce marked keratinocyte proliferation but do not stimulate normal keratinocyte differentiation (38, 39). In addition, both EGF and TGF-α inhibit the growth of hair follicles (40, 41), while EGF stimulates the growth of sebaceous (42) and sweat glands (43). In contrast, rhNDF-α2 has no apparent effect on any dermal adnexa, both in the rabbit ear excisional wound model and after systemic administration to newborn rats (Danilenko, D. M., and G. F. Pierce, unpublished data).

The epidermal effects of rhNDF-α2 are also in contrast with those induced by other growth factors having paracrine epidermal effects. Keratinocyte growth factor, a member of the fibroblast growth factor family (44), induces marked proliferation but less extensive epidermal migration than does rhNDF-α2 (28). Also in contrast with rhNDF-α2, keratinocyte growth factor directly stimulates hair follicles and sebaceous glands (28). Other growth factors which have been reported to stimulate wound reepithelialization in vivo are basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF). bFGF directly stimulates keratinocyte growth in vitro (45) and has similar in vivo effects, namely epidermal proliferation and a moderate increase in epidermal migration (27). PDGF does not appear to bind keratinocytes directly (46), but acts on the epidermis indirectly, presumably via the stimulation of dermal fibroblasts to produce paracrine growth factors with epidermal effects (27). In contrast with rhNDF-α2, both bFGF and PDGF stimulate epidermal proliferation (27).

TGF-β has some effects on the epidermis and keratinocytes which are very similar to those of rhNDF-α2. Like rhNDF-α2, TGF-β does not induce prominent sustained epidermal proliferation and can actually inhibit the growth of cultured keratinocytes in vitro (47). In addition, TGF-β also appears to increase keratinocyte integrin expression, specifically integrins α6β1 and α7β1 (48). Unlike rhNDF-α2, however, TGF-β decreases the rate of wound reepithelialization in vivo (27) and induces keratinocytes to assume a hyperproliferative phenotype in vitro (47) and to exhibit disorderly keratinization (dyserkeratosis) in vivo (26), while rhNDF-α2--treated wounds exhibit normal differentiation. Therefore, in contrast with all other currently known
growth factors known to have effects on the epidermis, rhNDF-\(\alpha_2\) is unique in its ability to accelerate the migration of normally differentiated epidermis without stimulating sustained epidermal proliferation.

In addition to demonstrating that rhNDF-\(\alpha_2\) accelerates epidermal migration in vivo, we have also shown that rhNDF-\(\alpha_2\) upregulates the distribution and expression of \(\alpha_5\) and \(\alpha_6\) integrins in the migrating neoeipidermis. During epidermal migration and differentiation associated with wound repair, the distribution of integrins such as \(\alpha_2\beta_1\), \(\alpha_5\beta_1\), and \(\alpha_5\beta_4\) increases in the migrating new epidermis to extend into suprabasal layers, while the surface expression of other integrins, such as \(\alpha_5\beta_1\) and \(\alpha_6\), is markedly increased in migrating keratinocytes (49–51). \(\alpha_5\) integrin associates with the \(\beta_1\) subunit in keratinocytes, where it serves as a receptor for fibronectin (36), one of the important components of the provisional extracellular matrix mediating keratinocyte migration in dermal wounds (52). \(\alpha_5\beta_1\) integrin is not expressed on normal, unactivated keratinocytes, but is upregulated in activated, migrating keratinocytes (50, 51, 53). In keratinocytes, \(\alpha_6\) integrin associates only with the \(\beta_4\) subunit and is localized within hemidesmosomes along the basal surface of unactivated basal keratinocytes where it serves as a

---

Figure 5. A, C, E, and G are serial sections of a control wound 5 d after wounding. B, D, F, and H are serial sections of a 5-d-old rhNDF-\(\alpha_2\)-treated wound. Original magnification, \(\times 20\) for A and B and \(\times 25\) for C–H. Arrow indicates wound margin. A and B are H&E stained and illustrate the marked increase in reepithelialization induced by rhNDF-\(\alpha_2\) (B) versus control (A). C and D are stained for filagrin, a marker of keratinocyte differentiation, and illustrate a marked increase in filagrin expression in the migrating new epidermis of the rhNDF-\(\alpha_2\)-treated wound (D) versus the control wound (C). E and F are stained for cytokeratin 10, another marker of keratinocyte differentiation, and illustrate an increase in cytokeratin 10 expression in the migrating new epidermis beyond the original wound margin (arrow) in the rhNDF-\(\alpha_2\)-treated wound (F) versus the control wound (E). G and H are stained for cytokeratin 14, a marker of undifferentiated keratinocytes, and illustrate that there are no differences in the expression of this marker in rhNDF-\(\alpha_2\)-treated wounds (H) versus control wounds (G).

Figure 6. Expression of \(\alpha_6\) (A and B) and \(\alpha_5\) (C and D) integrins in frozen sections of 5-d-old rhNDF-\(\alpha_2\)-treated and control wounds. Original magnification, \(\times 20\) for A and B and \(\times 62.5\) for C and D. Arrow indicates wound margin in A and B. Both control (A) and rhNDF-\(\alpha_2\)-treated (B) wounds exhibit suprabasal \(\alpha_6\) integrin expression in the migrating epidermis, with the rhNDF-\(\alpha_2\)-treated wound (B) exhibiting much more extensive suprabasal expression of \(\alpha_6\) integrin than the control wound (A). \(\alpha_5\) integrin is very weakly expressed in the migrating new epidermis of the control wound (C), but is moderately strongly expressed in both basal and suprabasal keratinocytes in the migrating new epidermis of the rhNDF-\(\alpha_2\)-treated wound (D).
Figure 7. Expression of HER-2/neu, HER-3, and two different epitopes of NDF in sections of rabbit ear. A and B are frozen sections stained for HER-2/neu expression, C and D are fixed sections stained for HER-3 expression, and E and F are frozen sections stained with two different anti-NDF mAbs. B, E, and F all illustrate the same ear wound. Original magnification, ×50 for A and C, ×20 for B, D, E, and F. Arrow indicates wound margin. A is normal skin and illustrates that HER-2/neu is expressed in basal and spinous layers of unwounded epidermis as well as in the basal layers of hair follicles and sebaceous glands. B is a wound margin and illustrates a marked decrease in HER-2/neu expression in wound neoeipidermis. C is normal skin and illustrates that HER-3 is weakly expressed in unwounded epidermal basal keratinocytes, but is strongly expressed in basal layers of hair follicles and sebaceous glands as well as by follicular keratin. D is a wound margin and illustrates that wound neoeipidermis exhibits a marked increase in both intensity and extent of HER-3 expression, in sharp contrast to the decreased neoeipidermal expression of HER-2/neu illustrated in B above. E is a wound margin stained with the NDF α isoform–specific mAb, 1H7A, and illustrates that dermal fibroblasts in both wounded and unwounded areas express α NDF isoforms. F is a wound margin stained with the mAb 1H8C, which recognizes both α and β isoforms of NDF, and illustrates a pattern of localization virtually identical to that of 1H7A in dermal fibroblasts in both wounded and unwounded areas.

receptor for laminin (35, 54, 55). In migrating keratinocytes, α6β4 integrin is one of the first adhesion molecules to appear when keratinocytes associate with connective tissue (55), and its distribution increases to include lateral as well as basal surfaces of all keratinocytes, both basal and suprabasal (49–51). In this activated state, keratinocyte α6β4 integrin is no longer a
receptor for laminin but associates with an as yet undetermined ligand, possibly epiligrin (55), a component of the basement membrane adhesion complex which is synthesized and left behind by cultured keratinocytes as they migrate (34). Our findings that rhNDF-α2 augments the increased distribution of α5β1 integrin expression normally seen in activated, migrating keratinocytes, as well as moderately increasing the expression of α6β4 in migrating keratinocytes, indicates that rhNDF-α2 may be an important mediator of early integrin upregulation by migrating keratinocytes. Furthermore, it suggests that the increased epidermal migration induced by rhNDF-α2 may be modulated by increased expression of integrins and other adhesion molecules in migrating keratinocytes.

While a previous study localized NDF to the skin by in situ hybridization, the resolution was too poor to enable precise identification of the region and cells which expressed NDF (23). In this study we have demonstrated that endogenous NDF is expressed in dermal fibroblasts in both wounded and unwounded skin. We have further shown that this endogenous dermal NDF is most likely an α NDF isoform(s) by virtue of essentially identical patterns of dermal fibroblast staining with the α isoform–specific mAb 1H7A and the mAb 1H8C, which recognizes both α and β NDF isoforms, coupled with the absence of a biologic effect with β NDF isoforms in dermal wounds.

We have extended previous studies (19–22) by demonstrating that HER-2/neu and HER-3 are both expressed in skin and dermal adnexa. We have also shown that HER-2/neu expression is markedly decreased in the migrating new epidermis, while neoeipidermal HER-3 expression is markedly increased. These findings suggest that the interaction of rhNDF-α2 with the HER-2/neu-Her-3 receptor complex in wounded epidermis induces a conformational change in the receptor complex such that expression of its direct receptor, HER-3, is upregulated while expression of its indirect receptor, HER-2/neu, is downregulated. The biologic significance of this change in receptor expression is unclear, but indirect stimulation and/or inhibition of HER-2/neu has been reported to occur in vitro via the formation of heterodimeric receptor complexes between HER-2/neu and EGFR (56), HER-2/neu and HER-3 (8, 9), and possibly between HER-2/neu and HER-4 (7).

The finding that only rhNDF-α2 has an in vivo effect on dermal wound reepithelialization suggests that NDF-α2 is the predominant endogenous NDF isoform in skin and plays a unique role in mediating dermal–epidermal interactions during cutaneous tissue repair. It further suggests that the different NDF isoforms exhibit different in vivo biologic activities in addition to having differing patterns of cell and tissue distribution. The finding that β isoforms of NDF do not appear to have any in vivo biologic activity in cutaneous tissue repair is not altogether unexpected, since these isoforms have been localized primarily to nervous tissue (16). The lack of in vivo biologic activity in our cutaneous tissue repair model with rhNDF-α1, however, was somewhat unanticipated and suggests that the differing biologic activities of individual NDF isoforms extend beyond those attributable solely to the differences between α and β isoforms. Further studies in different in vivo model systems will be required to more fully delineate the biologic roles of the different NDF isoforms.

In summary, this study is the first report describing an in vivo biologic effect for NDF and demonstrates that NDF, and specifically NDF-α2, is unique among currently known growth factors in its epidermal effects. In addition, our results suggest that endogenous NDF-α2 may function as an important paracrine mediator in directing initial epidermal migration during cutaneous tissue repair.

Acknowledgments

We thank Diane Duryea and Carol Burgh for excellent technical assistance, and Jennifer Keyser and Danette Barron for assistance with figures.

References

integrin
loss
terminal
a6,64
adhesion
keratinocyte
610.
Cell
major pathways
276:729-731.
biosensor
and kinetic
skin
C.
W.
acceleration of tissue
wound
Enhancement
of
III,
Curtsinger
growth
differentiation factor
adult
and vaccinia growth
basic
and F. M.
L.,
E., R. B.
M. Cramer,
L. J.
Klopchin,
D.
Yanagihara,
K.
Holbrook,
E.
J.
Holtzin,
F.,
C.
Curtsinger
III,
L.,
Holtzin,
G. S.
laminin
and F. M.
1993. Epidermal growth factor and vaccinia growth factor
enhanced
tissue
wound
healing
by transforming
growth factor-α and vaccinia growth factor. Science (Wash. DC).
235:350-352.
Brown, G.
Orr-Urtreger, A.,
23.
Maguire,
22.
Colvin,
21.
Brown, G.

Neu Differentiation Factor Upregulates Epidermal Migration and Integrin Expression

851